Literature DB >> 8202357

Activation of the immunoglobulin kappa 3' enhancer in pre-B cells correlates with the suppression of a nuclear factor binding to a sequence flanking the active core.

K B Meyer1, J Ireland.   

Abstract

Both the kappa intron and the kappa 3' enhancer are required for high levels of immunoglobulin kappa gene expression. The activity of both enhancer elements can be induced by LPS in pre-B cells. While the LPS induction of the kappa intron enhancer is mediated by NF-kappa B, this factor is not responsible for activation of the 3' enhancer. Dissection of the 3' enhancer has shown that in pre-B cells the activity of the kappa 3' enhancer is repressed by a region flanking an active core element. We have now scanned this flanking region for nuclear factor binding sites and have identified sites for B-cell specific E47/E12-like proteins and two ubiquitous nuclear proteins. Furthermore, we have identified a nuclear factor in pre-B cells whose binding activity is suppressed in response to LPS. In its tissue-distribution and binding specificity this factor appears to be identical to the lymphoid specific protein LEF-1. The position of the LEF-1 binding site within the 3' enhancer and its response to LPS raise the possibility that LEF-1 may be the target for a second pathway able to mediate LPS induction of immunoglobulin kappa gene transcription.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8202357      PMCID: PMC308032          DOI: 10.1093/nar/22.9.1576

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  36 in total

1.  Characterization of the human immunoglobulin kappa gene 3' enhancer: functional importance of three motifs that demonstrate B-cell-specific in vivo footprints.

Authors:  J G Judde; E E Max
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

2.  The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures.

Authors:  K Giese; J Cox; R Grosschedl
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

3.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

4.  Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein.

Authors:  Y Shi; E Seto; L S Chang; T Shenk
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

Review 5.  Immunoglobulin gene transcription.

Authors:  L M Staudt; M J Lenardo
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

6.  A physical map and analysis of the murine C kappa-RS region show the presence of a conserved element.

Authors:  B Müller; H Stappert; M Reth
Journal:  Eur J Immunol       Date:  1990-06       Impact factor: 5.532

7.  The hLEF/TCF-1 alpha HMG protein contains a context-dependent transcriptional activation domain that induces the TCR alpha enhancer in T cells.

Authors:  P Carlsson; M L Waterman; K A Jones
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

8.  Cloning and functional characterization of early B-cell factor, a regulator of lymphocyte-specific gene expression.

Authors:  J Hagman; C Belanger; A Travis; C W Turck; R Grosschedl
Journal:  Genes Dev       Date:  1993-05       Impact factor: 11.361

9.  Identification of enhancer sequences 3' of the rabbit Ig kappa L chain loci.

Authors:  N J Hole; N Harindranath; G O Young-Cooper; R Garcia; R G Mage
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

10.  Ly1+ PRO-B lymphocyte clones. Phenotype, growth requirements and differentiation in vitro and in vivo.

Authors:  R Palacios; H Karasuyama; A Rolink
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  8 in total

1.  BSAP can repress enhancer activity by targeting PU.1 function.

Authors:  S Maitra; M Atchison
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  Activation of c-myc promoter P1 by immunoglobulin kappa gene enhancers in Burkitt lymphoma: functional characterization of the intron enhancer motifs kappaB, E box 1 and E box 2, and of the 3' enhancer motif PU.

Authors:  N E Wittekindt; K Hörtnagel; C Geltinger; A Polack
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

3.  Cells strongly expressing Ig(kappa) transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers.

Authors:  B Goyenechea; N Klix; J Yélamos; G T Williams; A Riddell; M S Neuberger; C Milstein
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

4.  An enhancer LEF-1/TCF-1 site is essential for insertion site-independent transgene expression in thymus.

Authors:  T L Haynes; M B Thomas; M R Dusing; M T Valerius; S S Potter; D A Wiginton
Journal:  Nucleic Acids Res       Date:  1996-12-15       Impact factor: 16.971

5.  A developmentally modulated chromatin structure at the mouse immunoglobulin kappa 3' enhancer.

Authors:  M C Roque; P A Smith; V C Blasquez
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

6.  EBV-encoded LMP1 upregulates Igκ 3'enhancer activity and Igκ expression in nasopharyngeal cancer cells by activating the Ets-1 through ERKs signaling.

Authors:  Haidan Liu; Zhi Duan; Hui Zheng; Duosha Hu; Ming Li; Yongguang Tao; Ann M Bode; Zigang Dong; Ya Cao
Journal:  PLoS One       Date:  2012-03-01       Impact factor: 3.240

7.  LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells.

Authors:  HaiDan Liu; Hui Zheng; Zhi Duan; DuoSha Hu; Ming Li; SuFang Liu; ZiJian Li; XiYun Deng; ZhenLian Wang; Min Tang; Ying Shi; Wei Yi; Ya Cao
Journal:  Mol Cancer       Date:  2009-10-27       Impact factor: 27.401

8.  Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

Authors:  Kerstin B Meyer; Ana-Teresa Maia; Martin O'Reilly; Andrew E Teschendorff; Suet-Feung Chin; Carlos Caldas; Bruce A J Ponder
Journal:  PLoS Biol       Date:  2008-05-06       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.